Management of Esophageal Candidiasis

First‑Line Systemic Therapy

• Oral fluconazole 200 mg–400 mg on day 1, then 200 mg daily for 14–21 days (continue at least 14 days and ≥2 weeks after symptom resolution). This regimen is the treatment of choice for immunocompromised adults with esophageal candidiasis. 1
• Systemic antifungal therapy is required; topical agents alone are ineffective. Evidence from two guideline statements supports this requirement. 2, 3
• Clinical improvement is typically observed within 48–72 hours of initiating therapy. Rapid response aids early confirmation of diagnosis. 4
• Intravenous fluconazole (same dosing) is an effective alternative for patients unable to take oral medication. 4

Empiric (Diagnostic‑Trial) Therapy

• A therapeutic trial of fluconazole is appropriate before endoscopy when classic dysphagia/odynophagia co‑exists with oropharyngeal candidiasis. This approach is cost‑effective in immunocompromised populations due to the high prevalence of Candida esophagitis. 2, 3

Alternative First‑Line Options

• Itraconazole oral solution 200 mg daily for 14–21 days is effective but less well tolerated than fluconazole. 2, 3
• Itraconazole capsules and ketoconazole should be avoided because variable absorption makes them significantly less effective than fluconazole or itraconazole solution. 2, 3
• Echinocandin agents (for azole‑intolerant patients):
  
  • Micafungin 150 mg IV daily.
  • Caspofungin 70 mg IV loading dose, then 50 mg daily.
  • Anidulafungin 200 mg IV loading dose, then 100 mg daily.

Management of Fluconazole‑Refractory or Azole‑Resistant Disease

• Treatment failure is defined as persistent symptoms after 7–14 days of appropriate therapy. 4, 5
• Second‑line options for fluconazole‑refractory disease:
  
  • Itraconazole solution >200 mg daily – effective in ≈ ⅔ of refractory cases. 2, 3, 5
  • Posaconazole oral suspension 400 mg twice daily for 3 days, then 400 mg daily – effective in ≈ 75 % of azole‑refractory cases. 1, 5
  • Voriconazole 200 mg twice daily – recommended as an alternative azole. 1
• For azole‑resistant disease:
  
  • Echinocandins (micafungin, caspofungin, or anidulafungin) for 14–21 days. 1
  • Amphotericin B deoxycholate 0.3–0.7 mg/kg IV daily – reserved as a last‑resort therapy. 2, 3

Prevention of Recurrence (Secondary Prophylaxis)

• Chronic suppressive therapy is not routinely recommended because of concerns about resistance, drug interactions, and cost. 4, 5
• Indications for suppressive therapy include:
  
  • Disabling recurrent esophageal candidiasis.
  • Documented esophageal candidiasis with CD4 < 200 cells/µL (HIV‑infected patients).
  • Fluconazole‑refractory disease that responded to an echinocandin or other agent, pending immune reconstitution.
• Suppressive regimen: Fluconazole 100–200 mg three times weekly. 1, 5
• For HIV‑infected patients, antiretroviral therapy is strongly recommended as the most important intervention to prevent relapse. 1, 4, 5

Monitoring and Safety

• Liver function tests should be monitored periodically if azole therapy is expected to exceed 21 days. 4, 5
• Adverse‑effect profile:
  
  • Azoles – gastrointestinal upset and potential hepatotoxicity with prolonged use. 4
  • Echinocandins – generally well tolerated; possible infusion‑related histamine reactions, transient transaminase elevation, and rash. 5

Critical Pitfalls to Avoid

• Do not use itraconazole capsules or ketoconazole for esophageal candidiasis because of unpredictable absorption and inferior efficacy compared with fluconazole or itraconazole solution. 2, 3
• Avoid relying on topical therapy alone; systemic antifungal treatment is mandatory for cure. 2, 3
• In patients with advanced immunosuppression (CD4 < 50 cells/µL) who have received multiple azole courses, consider early use of echinocandins due to the risk of azole resistance. 5

Treatment of Esophageal Candidiasis

First-Line Treatment

• The Infectious Diseases Society of America recommends oral fluconazole 200-400 mg on day 1, followed by 200 mg daily for 14-21 days as the treatment of choice for esophageal candidiasis 6, 7
• Intravenous fluconazole at the same dosage can be used in patients unable to tolerate oral therapy, as recommended by the Centers for Disease Control and Prevention 8
• Treatment should continue for at least 14 days and for at least 2 weeks following resolution of symptoms, according to the European Society of Clinical Microbiology and Infectious Diseases 7, 9

Alternative Treatments for Fluconazole-Susceptible Candida

• The American College of Physicians suggests itraconazole oral solution 200 mg daily for 14-21 days as an effective alternative to fluconazole, although it is less well-tolerated 6
• Voriconazole 200 mg twice daily for 14-21 days is equally efficacious as fluconazole but has more adverse effects and drug interactions, as reported by the Infectious Diseases Society of America 7, 9
• Posaconazole oral solution or extended-release tablets can be considered for refractory cases, as recommended by the Centers for Disease Control and Prevention 6, 10

Treatment for Fluconazole-Refractory Disease

• For fluconazole-refractory esophageal candidiasis, the Infectious Diseases Society of America recommends echinocandins for 14-21 days, including micafungin 150 mg daily, caspofungin 70 mg loading dose followed by 50 mg daily, and anidulafungin 200 mg daily 6
• Amphotericin B deoxycholate 0.3-0.7 mg/kg daily for 21 days is another option for refractory disease, as suggested by the American College of Physicians 6

Special Considerations

• For HIV-infected patients, the Centers for Disease Control and Prevention strongly recommends antiretroviral therapy to reduce the incidence of recurrent infections 6, 10
• For patients with recurrent esophageal candidiasis, the Infectious Diseases Society of America recommends chronic suppressive therapy with fluconazole 100-200 mg three times weekly 6
• Diagnostic endoscopy may not be necessary before initiating therapy if patients have typical symptoms and oropharyngeal candidiasis is present, according to the European Society of Clinical Microbiology and Infectious Diseases 7, 9

Monitoring and Follow-up

• Most patients show clinical improvement within 48-72 hours of starting therapy, as reported by the Centers for Disease Control and Prevention 10
• If prolonged azole therapy (>21 days) is anticipated, periodic monitoring of liver function tests should be considered, as recommended by the Centers for Disease Control and Prevention 10, 8
• Echinocandins appear to be safe with minimal side effects but are associated with higher relapse rates compared to fluconazole, according to the Infectious Diseases Society of America 10, 8
• Treatment failure is defined as persistence of symptoms after 7-14 days of appropriate therapy, as defined by the Centers for Disease Control and Prevention 11, 10

Common Pitfalls and Caveats

• Itraconazole capsules and ketoconazole are less effective than fluconazole due to variable absorption and should not be used if other options are available, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 7, 10
• Echinocandins, while effective, are associated with higher relapse rates than fluconazole and are only available parenterally, according to the Centers for Disease Control and Prevention 10, 9

Initial Therapy for Azole‑Resistant Esophageal Candidiasis

Preferred Antifungal Choice

• In patients who have recent azole exposure or are known to be infected with azole‑resistant Candida species, initiating treatment with an echinocandin (e.g., micafungin, caspofungin, or anidulafungin) is recommended over fluconazole as the first‑line therapy. 12